SG11202003912RA - Single Domain Antibodies that Bind to CD137 - Google Patents

Single Domain Antibodies that Bind to CD137

Info

Publication number
SG11202003912RA
SG11202003912RA SG11202003912RA SG11202003912RA SG11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA
Authority
SG
Singapore
Prior art keywords
bind
single domain
domain antibodies
antibodies
domain
Prior art date
Application number
SG11202003912RA
Other languages
English (en)
Inventor
Verena Brucklacher-Waldert
Carolyn Edwards
James Legg
Jayesh Majithiya
Brian Mcguinness
Christine Rossant
Yumin Teng
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718734.5A external-priority patent/GB201718734D0/en
Priority claimed from GBGB1718735.2A external-priority patent/GB201718735D0/en
Priority claimed from GBGB1808589.4A external-priority patent/GB201808589D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of SG11202003912RA publication Critical patent/SG11202003912RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SG11202003912RA 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137 SG11202003912RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1718734.5A GB201718734D0 (en) 2017-11-13 2017-11-13 Single domain antibodies that bind to CD137
GBGB1718735.2A GB201718735D0 (en) 2017-11-13 2017-11-13 Bispecific molecules that bind to CD137 and PSMA
GBGB1808589.4A GB201808589D0 (en) 2018-05-24 2018-05-24 Single domain antibodies that bind CD137
PCT/GB2018/053279 WO2019092451A1 (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137

Publications (1)

Publication Number Publication Date
SG11202003912RA true SG11202003912RA (en) 2020-05-28

Family

ID=64457031

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202003978UA SG11202003978UA (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma
SG11202003912RA SG11202003912RA (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202003978UA SG11202003978UA (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma

Country Status (10)

Country Link
US (2) US20200362051A1 (ja)
EP (2) EP3710477A1 (ja)
JP (3) JP7312168B2 (ja)
KR (2) KR20200083574A (ja)
CN (2) CN111699197A (ja)
AU (2) AU2018363291A1 (ja)
CA (2) CA3082321A1 (ja)
IL (2) IL274370A (ja)
SG (2) SG11202003978UA (ja)
WO (2) WO2019092451A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236174B2 (en) 2016-01-12 2022-02-01 Crescendo Biologics Limited Therapeutic molecules
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
EP3565840A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
EP3710477A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
JP2020132572A (ja) * 2019-02-20 2020-08-31 旭化成株式会社 シラノール組成物、硬化物及び製造方法
AU2020275926A1 (en) * 2019-05-15 2021-11-18 Crescendo Biologics Limited Binding molecules
EP3853257A4 (en) * 2019-08-12 2022-06-29 I-Mab Biopharma US Limited Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
US20220411523A1 (en) * 2019-11-13 2022-12-29 Hefei Hankemab Biotechnology Co., Ltd Molecule capable of binding to human 4-1bb and its application thereof
KR20220114560A (ko) * 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 항-cd79 키메라 항원 수용체, car-t 세포 및 이의 용도
KR20230013125A (ko) * 2020-06-30 2023-01-26 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 4-1bb 결합 단백질 및 이의 용도
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
EP4341294A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
EP4341293A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-cd137 antibodies and methods of use
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用
IL311144A (en) * 2021-08-31 2024-04-01 Lanova Medicines Ltd Anti-1-4BB Nanobodies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP2310526A4 (en) * 2008-07-18 2011-11-02 Oragenics Inc COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2874309C (en) * 2012-05-24 2021-06-15 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
TWI726842B (zh) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
CN114774466A (zh) 2014-10-22 2022-07-22 克雷森多生物制剂有限公司 转基因小鼠
SG11201708334RA (en) * 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CN108112253B (zh) * 2015-05-18 2022-09-23 皮里斯制药有限公司 抗癌融合多肽
AU2016334623A1 (en) * 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
SG11201805532XA (en) * 2016-01-11 2018-07-30 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
US11236174B2 (en) * 2016-01-12 2022-02-01 Crescendo Biologics Limited Therapeutic molecules
RU2018139339A (ru) * 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
US20170342169A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins
AU2018348429A1 (en) * 2017-10-10 2020-03-12 Numab Therapeutics AG Multispecific antibody
EP3710477A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137

Also Published As

Publication number Publication date
EP3710478A1 (en) 2020-09-23
CN111699197A (zh) 2020-09-22
JP2021502104A (ja) 2021-01-28
AU2018363291A1 (en) 2020-05-21
WO2019092451A1 (en) 2019-05-16
KR20200083574A (ko) 2020-07-08
IL274371A (en) 2020-06-30
CA3082321A1 (en) 2019-05-16
JP7312168B2 (ja) 2023-07-20
AU2018363292A1 (en) 2020-05-21
US20200362047A1 (en) 2020-11-19
US20200362051A1 (en) 2020-11-19
IL274370A (en) 2020-06-30
EP3710477A1 (en) 2020-09-23
JP2021502810A (ja) 2021-02-04
CN111683968A (zh) 2020-09-18
KR20200080304A (ko) 2020-07-06
JP2023126951A (ja) 2023-09-12
WO2019092452A1 (en) 2019-05-16
SG11202003978UA (en) 2020-05-28
CA3082297A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
IL274370A (en) Single-region antibodies that bind CD137
IL284336B (en) Treatment using antibodies that bind to ctla4
IL276537A (en) Antibodies bind to GPRC5D
IL254088A0 (en) Cure using cd137 binding antibody
IL261188A (en) Antibodies against tigit
HK1252863A1 (zh) 結合cd22的抗體分子
HK1252862A1 (zh) 結合cd45的抗體分子
IL254260A0 (en) A healing antibody that binds tim3
IL275268A (en) Antibodies against LILRB2
EP3325009A4 (en) Antibody therapeutics that bind lag3
HK1256300A1 (zh) 特異性地結合至tl1a的抗體
EP3247407A4 (en) Non-immunogenic single domain antibodies
ZA201907065B (en) Monoclonal antibody to pd-l1
EP3297662A4 (en) ANTIBODY BINDING TO AXL PROTEINS
IL269394A (en) Antibodies bind to STEAP-1
EP3131580A4 (en) Antibody therapeutics that bind cd147
IL273235A (en) Heavy chain antibodies that bind to ectoenzymes
GB201609742D0 (en) Improvements relating to antibodies
EP3297663A4 (en) Antibodies that bind to axl proteins
ZA202002044B (en) Monoclonal antibody to il-5rα
SG10202010600SA (en) T cell receptor like antibodies that bind to p53-mhc class i complex
GB201718734D0 (en) Single domain antibodies that bind to CD137
GB201808589D0 (en) Single domain antibodies that bind CD137
IL272015A (en) Antibodies to MADCAM
GB201718735D0 (en) Bispecific molecules that bind to CD137 and PSMA